Trial Profile
AFX01-14: A Phase 3, Randomized, Active-controlled, Open-label, Multi-center Study of the Safety and Efficacy of Peginesatide for the Maintenance Treatment of Anemia in Hemodialysis Patients Previously Treated With Epoetin
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Oct 2021
Price :
$35
*
At a glance
- Drugs Peginesatide (Primary) ; Epoetin alfa; Epoetin beta
- Indications Anaemia
- Focus Therapeutic Use
- Acronyms EMERALD 2
- Sponsors Affymax
- 23 May 2014 New trial record